INmune Bio (INMB) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Fri, May 8, 2026 astatine 9:30 AM CDT 7 min read

Image source: The Motley Fool.

Date

Thursday, May 7, 2026 astatine 4:30 p.m. ET

Call participants

• Chief Executive Officer — David Moss

• Chief Scientific Officer — Mark Lowdell

• Chief Financial Officer — Cory Ellspermann

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

David Moss: Thank you, Daniel, and bully afternoon, everyone. For our archetypal 4th 2026 net call, today, I'll reappraisal cardinal takeaways and supply an update connected our level programs. Following my reappraisal of caller developments astatine INmune Bio, I volition walk the microphone to Dr. Lowdell, INmune Bio's CSO and inventor of CORDStrom, who volition supply an update connected our CORDStrom MSC level and peculiarly our RDEB program. Next, Cory Ellspermann volition supply our fiscal results, aft which I'll reason our prepared remarks. We entered 2026 with wide priorities and beardown momentum crossed our platforms. Most importantly, our CORDStrom level remains connected track, and we are present approaching a cardinal milestone with our regulatory filings.

Based connected the advancement of our analyses, manufacturing readiness and regulatory preparation, we expect to record for support opening successful the adjacent term, and we stay assured successful the clip enactment that we antecedently outlined. CORDStrom represents a imaginable archetypal systemic therapy for RDEB, and we judge the information proceed to enactment some its objective benefits and its broader level potential. Execution against this filing is our apical priority. Turning to XPro. While CJ is not speaking today, I privation to stress that we proceed to marque meaningful progress. We are advancing further imaging investigation from the MINDFuL study, including MRI information focused connected myelin preservation and structural integrity.

These information sets are important arsenic they further qualify XPro's imaginable arsenic a disease-modifying therapy. At the aforesaid time, we're exploring imaginable uncommon illness trials for XPro and imaginable partners arsenic we specify the way forward, including regulatory alignment late-stage improvement strategies. Naturally, we'll update the markets arsenic these milestones develop. Overall, we judge we're good positioned crossed some platforms arsenic we determination done a catalyst-rich play for the institution and a marked alteration perchance for the institution arsenic we get person to commercialization. With that, I'll crook the telephone implicit to Mark Lowdell to supply much details connected CORDStrom. Mark?

Mark Lowdell: Thank you, David, and convey you to everyone that's joined the call. As David said, since our past net call, we've moved guardant importantly successful bringing CORDStrom to market, and it is our cardinal aim. First, we submitted the pediatric probe program known arsenic a PIP to the U.K. medicines regulator successful February, and we were approved for accelerated appraisal and receiving their effect connected the 9th of April. No important issues were raised, and we expect submitting our last effect successful the adjacent fewer days. The support of the PIP is an indispensable measurement to implicit anterior to submission of the selling authorization exertion successful the U.K. and past to the EMA for Europe.